Immunotherapy with B28, an antibody to Aβ oligomers, potently decreases amyloid plaques, microgliosis, and memory decline in APP knock-in mice
knock-in mice, weekly infusions of B28 for four months markedly reduced both amyloid plaques and Aβ oligomers, attenuated plaque-associated astrocytosis and microgliosis, preserved neurons, and lessened memory decline. Biochemical and histological analyses showed that B28 engaged both plaque-bound and diffusible Aβ, forming immune complexes and depleting free Aβ. In in vitro immunoassays, B28 had significantly higher affinity and captured more Aβ from AD brain extracts than did lecanemab. B28 is a potent, aggregate-preferring Aβ antibody that clears plaques and decreases gliosis, supporting its clinical development.
Authors
- Laurent Pradier (ORCID: https://orcid.org/0000-0001-6022-0951)
- Youqi Tao
- Dominic M. Walsh (ORCID: https://orcid.org/0000-0002-0718-6261)
- Beth L. Ostaszewski
- Dennis J. Selkoe (ORCID: https://orcid.org/0000-0001-8846-9767)
- Shaomin Li (ORCID: https://orcid.org/0000-0001-9451-2151)
- Ting Yang (ORCID: https://orcid.org/0009-0007-2681-0094)
- A.E. Francis
- Yi Ran Xu
- Cynthia A. Lemere
- Trebor L. Lawton
- David Reczek
- Shanxue Jin
- Jean-Pierre Bellier
- Andrew M. Stern
Institutions
- Brigham and Women's Hospital (US)
- Sanofi (France) (FR)
- US Biologic (United States) (US)
Publication Details
- Journal
- Cell Reports
- Published
- 2026-06-30
- DOI
- https://doi.org/10.1016/j.celrep.2026.117599
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Foundation for the National Institutes of Health
- National Institutes of Health